1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO 23: Pluvicto Fulfils Promise For Prostate Cancer Label Expansion

 
• By Kevin Grogan

Novartis' radioligand therapy has performed well against standard-of-care androgen-receptor pathway inhibitor therapy and could potentially be a paradigm shift in the treatment of prostate cancer.

Novartis HQ
• Source: Novartis

Observers eagerly awaiting the full dataset from the Phase III PSMAfore study of Novartis AG's prostate cancer radioligand therapy Pluvicto have had an early peek at what look like very promising results after all the late-breaking abstracts for the European Society for Medical Oncology (ESMO) meeting in Madrid were released early following a leak.

The Swiss major delivered positive topline data at the end of last year from 469-patient PSMAfore which showed that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) demonstrated a significant improvement in radiographic progression-free survival (rPFS) in men with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA+ mCRPC) after treatment with an androgen-receptor pathway inhibitor (ARPI) such as Pfizer Inc./Astellas Pharma, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.